We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Aquestive Therapeutics (AQST - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Aquestive Therapeutics is a member of the Medical sector. This group includes 956 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Aquestive Therapeutics is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for AQST's full-year earnings has moved 11.8% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, AQST has gained about 93.3% so far this year. Meanwhile, the Medical sector has returned an average of 0.2% on a year-to-date basis. This shows that Aquestive Therapeutics is outperforming its peers so far this year.
One other Medical stock that has outperformed the sector so far this year is Arcturus Therapeutics (ARCT - Free Report) . The stock is up 25.2% year-to-date.
In Arcturus Therapeutics' case, the consensus EPS estimate for the current year increased 11.5% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Aquestive Therapeutics belongs to the Medical - Drugs industry, which includes 146 individual stocks and currently sits at #78 in the Zacks Industry Rank. This group has gained an average of 7.3% so far this year, so AQST is performing better in this area.
On the other hand, Arcturus Therapeutics belongs to the Medical - Biomedical and Genetics industry. This 470-stock industry is currently ranked #88. The industry has moved +8.2% year to date.
Aquestive Therapeutics and Arcturus Therapeutics could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Aquestive Therapeutics (AQST - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Aquestive Therapeutics is a member of the Medical sector. This group includes 956 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Aquestive Therapeutics is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for AQST's full-year earnings has moved 11.8% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, AQST has gained about 93.3% so far this year. Meanwhile, the Medical sector has returned an average of 0.2% on a year-to-date basis. This shows that Aquestive Therapeutics is outperforming its peers so far this year.
One other Medical stock that has outperformed the sector so far this year is Arcturus Therapeutics (ARCT - Free Report) . The stock is up 25.2% year-to-date.
In Arcturus Therapeutics' case, the consensus EPS estimate for the current year increased 11.5% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Aquestive Therapeutics belongs to the Medical - Drugs industry, which includes 146 individual stocks and currently sits at #78 in the Zacks Industry Rank. This group has gained an average of 7.3% so far this year, so AQST is performing better in this area.
On the other hand, Arcturus Therapeutics belongs to the Medical - Biomedical and Genetics industry. This 470-stock industry is currently ranked #88. The industry has moved +8.2% year to date.
Aquestive Therapeutics and Arcturus Therapeutics could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.